A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Deucravacitinib — DRUG
  As prescribed by treating clinician

Study Details

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

Key Dates

First listed

Nov 22, 2024

Start date

Jan 29, 2025

Status verified

May 2026

Primary completion

Apr 30, 2028

Completion

Apr 30, 2028

Study Design

Enrollment

350 participants (estimated)

Arms

• Arm: Participants that have initiated deucravacitinib treatment

Primary Outcome Measure

Physician's Global Assessment (PGA) 0/1 response [ Time Frame: Baseline and at months 4, 12, 18 (optional), and 24 ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey